Publications

Symptomatic Zika virus infection in infants, children, and adolescents living in Puerto Rico

2018

Authors: Read JS, Torres-Velasquez B, Lorenzi O, et al.

Published in: JAMA Pediatr. 2018;172(7):686-693

Importance  Little information is available regarding Zika virus (ZIKV) infection in children.

Objective  To describe patients younger than 18 years who were infected with ZIKV and were enrolled in the Sentinel Enhanced Dengue and Acute Febrile Illness Surveillance System (SEDSS).

Genetic evidence of Zika virus in mother’s breast milk and body fluids of a newborn with severe congenital defects

2018

Authors: Giovanetti M, Goes de Jesus J, Lima de Maia M, Junior JX, et al.

Published in: Clin Microbiol Infect.2018;24(10):1111-1112

Abstract On the basis of the upsurge in the number of newborns with neurologic disorders in the northeast, in November 2015 the Brazilian Ministry of Health declared a public health emergency of national concern [1].

Clinical and laboratory profile of Zika and dengue infected patients: lessons learned from the co-circulation of dengue, Zika and chikungunya in Brazil

2018

Authors: Azeredo EL, dos Santos FB, Barbosa LS, et al.

Published in: PLoS Curr. 2018 Feb 15;10

Background The current triple epidemic caused by dengue, zika and chikungunya constitutes a serious health problem in Brazil. The aim of this study was to investigate acute samples (up to the 7 days of symptoms) from patients presenting acute fever syndrome suspected as arboviral infection and characterize the clinical and laboratorial profile during the co-circulation of dengue,

Human T cell responses to Dengue and Zika virus infection compared to Dengue/Zika coinfection

2018

Authors: Badolato-Corrêa J, Sánchez-Arcila JC, et al.

Published in: Immun Inflamm Dis.2018; 6(2):194–206

Introduction Zika virus (ZIKV) and dengue virus (DENV) co‐circulated during latest outbreaks in Brazil, hence, it is important to evaluate the host cross‐reactive immune responses to these viruses. So far, little is known about human T cell responses to ZIKV and no reports detail adaptive immune responses during DENV/ZIKV coinfection.

Steady-state pharmacokinetics and early safety data in HIV-infected African children weighing 14 to <25kg on film-coated dolutegravir 25mg tablets

2018

Authors: Bollen P, Turkova A, Hilda Mujuru H, et al. The ODYSSEY Trial Team

Published in: 10th International Workshop on HIV Pediatrics, Amsterdam, 20-21st July 2018. Poster Number 22

ODYSSEY: design, current status, and baseline characteristics

2018

Authors: Moore CL,  Kekitinwa A, Kaudha E, et al; the ODYSSEY Trial Team

Published in: 10th International Workshop on HIV Pediatrics, Amsterdam, July 20-21st, 2018. Poster Number 34

Evidence for multiple sylvatic transmission cycles during the 2016-2017 yellow fever virus outbreak, Brazil

2018

Authors: Moreira-Soto A, Torres MC, Lima de Mendonça MC, et al.

Published in: Clin Microbiol Infect. 2018;24(9):1019.e1-1019.e4

Objectives Since December 2016, Brazil has experienced an unusually large outbreak of yellow fever (YF). Whether urban transmission may contribute to the extent of the outbreak is unclear. The objective of this study was to characterize YF virus (YFV) genomes and to identify spatial patterns to determine the distribution and origin of YF cases in Minas Gerais,

“I failed to take them as I should and now I’m scared”: how can we support adolescents’ adherence on second line HIV treatment

2018

Authors: Bernays S, Namukwaya S, Mupambireyi Z, Nanduudu A, Mujuru H, Turkova A, Gibb DM, Seeley J, and the ODYSSEY Trial Team.

Published in: 10th International Workshop on HIV Pediatrics, Amsterdam, July 20-21st 2018. Poster number 117

Steady-state pharmacokinetics and early safety data in HIV-infected African children weighing ≥25kg after switching to 50mg film-coated dolutegravir tablets in the ODYSSEY trial

2018

Authors: Turkova A, Bollen P, Kaudha E, et al. The ODYSSEY Trial Team

Published in: Oral Presentation at 10th International Workshop on HIV Pediatrics, Amsterdam, July 20-21st, 2018

Seroprevalence of dengue, chikungunya and Zika viruses in an antenatal population in the greater Kingston metropolitan region of Jamaica

2018

Authors: Anzinger J, Christie CD, Brown D, Bispo A, Nastouli E, Kozlakidis Z, Thorne C, Ades T, Lundin R, Giaquinto C

Published in: 2nd International Conference on Zika Virus and Aedes Related Infections, June 14th – 17th 2018, Tallin-Estonia

 

 

 

Investigating vertical transmission of chikungunya, dengue and zika virus infection: a prospective observational cohort study of pregnant women and infants in Jamaica

2018

Authors: Christie CD, Thorne C, Anzinger J, Bailey H, Palmer P, Morgan O, Bryan L, Mair S, Pierre R, Onyonyor A, Mitchell P, Melbourne-Chambers R, Webster-Kerr K, Lindo J, Lundin R, Brown D, Bispo A, Nastouli E, Giaquinto C

Published in: International Symposium on Zika Virus Research, June 4th – 6th 2018, Marseille – France

 

 

Evidence for mother-to-child transmission of Zika virus through breast milk

2018

Authors: Blohm GM, Lednicky JA, Márquez M, et al.

Published in: Clin Infect Dis. 2018;66(7):1120-1121

Abstract Zikavirus (ZIKV) is an emerging viral pathogen that continues to spread throughout different regions of the world. Herein we report a case that provides further evidence that ZIKV transmission can occur through breastfeeding by providing a detailed clinical,

Time of ART initiation in perinatally HIV-infected children impacts on HIV-specific T cell functionality

2018

Authors: Rinaldi S, Cotugno N, Pallikkuth S, Pahwa R, Palma P, Pahwa S

Published in:

Abstract Early initiation of antiretroviral therapy (ART) in vertically HIV-infected children provides an opportunity to limit the size of HIV reservoir. However, how the time of ART initiation impacts host HIV-specific immune responses is still poorly understood.

Time to viral rebound after stopping art in children treated from infancy in cher

2018

Authors: Violari A, Chan M, Otwombe KN, Panchia R, Jean-Philippe P, Gibb D, Cotton M, Babiker A

Published: Oral presentation at 25th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2018 – Boston. 

Abstract We investigated factors associated with time to viral rebound in children in CHER who started ART at age <12 weeks and received 40 (ART-40W) or 96 weeks (ART-96W) of primary therapy.

Lasting immune impacts of age at start of ART in vertically HIV-infected adolescents

2018

Authors: Cameron M, Rinaldi S, Richardson B, Cotugno N, Williams S, Pallikkuth S, de Armas LR, Cameron C, Pahwa R, Palma P, Pahwa S

Published: 25th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2018 – Boston. P_868

Abstract The study explores the impact of early ART on host immune response looking at HIV-specific CD4 T cell functionality and host transcriptome analysis.

Factors associated with HIV DNA levels in children starting antiretroviral therapy (ART) early in infancy

2018

Authors: Chan M, Tagarro A, Zangari P, Ferns B, Foster C, De Rossi A, Nastouli E, Ángeles Muñoz-Fernández M, Gibb D, Rossi P, Giaquinto C, Babiker A , Palma P, Rojo Conejo P

Published: 25th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2018 – Boston. P_ 866

Abstract The study focused on the determinants of low viral reservoir in a large cohort of European early treated HIV-1 infected children.

First report of dolutegravir unbond plasma concentrations during pregnancy in HIV-positive women

2018

Authors: Bollen P, Colbers A, Schalkwijk S, Velthoven-Graafland K, Konopnicki D, Weizsacker K, Hidalgo Tenorio C, van Crevel R, Burger D, on behalf of the PANNA network

Published: Oral presentation at 19th edition of the International Workshop on Clinical Pharmacology of Antiviral Therapy, May 22nd-24th 2018, Baltimore

 

Elvitegravir pharmacokinetics during pregnancy and postpartum

2018

Authors: Colbers A, Schalkwijk S, Konopnicki D, Rockstroh  J, Burger D, on behalf of the PANNA network

Published: Oral presentation at 19th edition of the International Workshop on Clinical Pharmacology of Antiviral Therapy, May 22nd-24th 2018, Baltimore.

 

Human Immunodeficiency Virus (HIV) – Antibody Repertoire Estimates Reservoir Size and Time of Antiretroviral Therapy Initiation in Virally Suppressed Perinatally HIV-Infected Children

2018

Authors: Rocca S, Zangari P, Cotugno N, et al.

Published in: J Pediatric Infect Dis Soc.2018; 28. doi:10

Background Assays to estimate human immunodeficiency virus (HIV) reservoir size require large amounts of blood, which represents a drawback especially in pediatric settings. We investigated whether HIV-antibody repertoire could estimate the viral reservoir size. Moreover, we assessed the magnitude of HIV-antibody response as a predictor of time of antiretroviral therapy (ART) initiation.

HIV specific IgM memory B-cells dominate in seronegative early-treated children

2018

Authors: Cotugno N, Morrocchi E, Pepponi I, Rocca S, Cameron M, Rinaldi S, Di Cesare S, Pallikkuth S, Bernardi S, Klein N, Ananworanich J, Rossi P, Pahwa S, Palma P

Published25th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2018 – Boston. P_ 866

Abstract This fascinating study investigates whether HIV specific B cells persist in seronegative HIV infected seronegative patients and what are the associated gene signatures after re-encountering the virus.

Early and highly suppressive ART are main factors associated with low viral reservoir in European perinatally HIV infected children

2018

Authors: Tagarro A, Chan M, Zangari P, et al; on behalf of the EPIICAL Consortium

Published in: J Acquir Immune Defic Syndr. 2018;79(2):269-276

Background Future strategies aiming to achieve HIV-1 remission are likely to target individuals with small reservoir size.

Setting We retrospectively investigated factors associated with HIV-1 DNA levels in European,

Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study

2018

Authors: Judd A, Chappell E, Turkova A; for European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord.

Published in: PLoS Med. 2018;15(1): e1002491

Background Published estimates of mortality and progression to AIDS as children with HIV approach adulthood are limited. We describe rates and risk factors for death and AIDS-defining events in children and adolescents after initiation of combination antiretroviral therapy (cART) in 17 middle- and high-income countries,

Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs.

2018

Authors: IeDEA and COHERE Cohort Collaborations.

Published in: Clin Infect Dis. 2018;66(6):893-903.

Background Early initiation of combination antiretroviral therapy (cART), at higher CD4 cell counts, prevents disease progression and reduces sexual transmission of human immunodeficiency virus (HIV). We describe the temporal trends in CD4 cell counts at the start of cART in adults from low-income,

Plasma and CSF pharmacokinetics of meropenem in neonates and young infants : results from the NeoMero studies

2018

Authors: Germovesk E, Lutsar I, Kipepr K, et al.; for NeoMero Consortium

Published in: J Antimicrob Chemother. 2018;73(7):1908-1916

Background Sepsis and bacterial meningitis are major causes of mortality and morbidity in neonates and infants. Meropenem a broad-spectrum antibiotic, is not licensed for use in neonates and infants below 3 months of age and sufficient information on its plasma and CSF disposition and dosing in neonates and infants is lacking.

Surveillance for control of antimicrobial resistance

2018

Authors: Tacconelli E, Sifakis F, Harbarth S, et al; for EPI-Net COMBACTE-MAGNET Group

Published in: Lancet Infect Dis. 2018;18(3):e99-e106.

Abstract Antimicrobial resistance poses a growing threat to public health and the provision of health care. Its surveillance should provide up-to-date and relevant information to monitor the appropriateness of therapy guidelines, antibiotic formulary, antibiotic stewardship programmes, public health interventions,

Effects of clinical pathway implementation on antibiotic prescription for pediatric community-acquired pneumonia

2018

Authors: Donà D, Zingarella S, Gastaldi A, et al.

Published in: PLoS One. 2018;13(2):e0193581. 

Background Italian pediatric antimicrobial prescription rates are among the highest in Europe. As a first step in an Antimicrobial Stewardship Program, we implemented a Clinical Pathway (CP) for Community Acquired Pneumonia with the aim of decreasing overall prescription of antibiotics, especially broad-spectrum.

Materials and Methods The CP was implemented on 10/01/2015.

Strategies for prevention of mother-to-child transmission adopted in the “real-world” setting: data from the italian register for HIV-1 infection in children.

2018

Authors: Chiappini E, Galli L, Lisi C, et al.

Published in: J Acquir Immune Defic Syndr. 2018;79(1):54-61.

Background Strategies for prevention of HIV-1 mother-to-child transmission (PMTCT) have been continuously optimized. However, cases of vertical transmission continue to occur in high-income countries.

Objectives To investigate changes in PMTCT strategies adopted by Italian clinicians over time and to evaluate risk factors for transmission.

Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial

2018

Authors: Mallewa J, Szubert AJ, Mugyenyi P, et al.

Published in: Lancet HIV. 2018;5(5):e231-e240

Background In sub-Saharan Africa, severely immunocompromised HIV-infected individuals have a high risk of mortality during the first few months after starting antiretroviral therapy (ART). We hypothesise that universally providing ready-to-use supplementary food (RUSF) would increase early weight gain, thereby reducing early mortality compared with current guidelines recommending ready-to-use therapeutic food (RUTF) for severely malnourished individuals only.

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: a randomised controlled trial

2018

Authors: Kityo C, Szubert AJ, Siika A, et al.

Published in: PLoS Med. 2018; 15(12):e1002706

Background In sub-Saharan Africa, individuals infected with HIV who are severely immunocompromised have high mortality (about 10%) shortly after starting antiretroviral therapy (ART). This group also has the greatest risk of morbidity and mortality associated with immune reconstitution inflammatory syndrome (IRIS),

Causes and timing of mortality and morbidity among late presenters starting antiretroviral therapy in the REALITY trial

2018

Authors: Post FA, Szubert AJ, Prendergast AJ, et al; for Reduction of early mortality in HIV-infected adults and children starting an antiretroviral therapy (REALITY) trial team

Published in: Clin Infect Dis. 2018;66(2):S132-S139

Background In sub-Saharan Africa, 20%-25% of people starting antiretroviral therapy (ART) have severe immunosuppression; approximately 10% die within 3 months. In the Reduction of EArly mortaLITY (REALITY) randomized trial,

Late presentation with HIV in Africa: phenotypes, risk, and risk stratification in the REALITY Trial

2018

Authors: Siika A, McCabe L, Bwakura-Dangarembizi M, et al; for REALITY Trial Team

Published in: Clin Infect Dis. 2018;66(2):S140-S146

Background Severely immunocompromised human immunodeficiency virus (HIV)–infected individuals have high mortality shortly after starting antiretroviral therapy (ART). We investigated predictors of early mortality and “late presenter” phenotypes.

Methods The Reduction of EArly MortaLITY (REALITY) trial enrolled ART-naive adults and children ≥5 years of age with CD4 counts <100 cells/μL initiating ART in Uganda,

Migrant women living with HIV in Europe: are they facing inequalities in the prevention of mother-to-child-transmission of HIV?: The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord

2018

Authors: Favarato G, Bailey H, Burns F, et al.

Published in: Eur J Public Health. 2018;28(1):55-60

Background In pregnancy early interventions are recommended for prevention of mother-to-child-transmission (PMTCT) of HIV. We examined whether pregnant women who live with HIV in Europe and are migrants encounter barriers in accessing HIV testing and care.
Methods Four cohorts within the European Pregnancy and Paediatric HIV Cohort Collaboration provided data for pooled analysis of 11 795 pregnant women who delivered in 2002–12 across ten European countries.

Time to switch to second-line antiretroviral therapy in children with HIV in Europe and Thailand

2018

Authors: European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord.

Published in: Clin Infect Dis. 2018;66(4):594-603.

Background Global data on durability of first-line antiretroviral therapy (ART) in children with HIV is limited. We assessed time to switch to second-line therapy in 16 European countries and Thailand.

Methods Children <18-years initiating combination ART (≥2 nucleoside reverse transcriptase inhibitor (NRTI) plus non-NRTI (NNRTI) or boosted-protease inhibitor (PI)) were included.

What we know and what we don’t know about perinatal Zika virus infection: a systematic review

2018

Authors: Soriano-Arandes A, Rivero-Calle I, Nastouli E, et al.

Published inExpert Rev Anti Infect Ther. 2018;16(3):243-254

Introduction: Zika virus (ZIKV) infection has caused the most challenging worldwide infectious epidemic outbreak in recent months. ZIKV causes microcephaly and other congenital malformations. There is a need to perform updated systematic reviews on ZIKV infection periodically because this epidemic is bringing up new evidence with extraordinary speed.

Report from the First EPIICAL General Assembly meeting, 9–11 November 2017, Rome, Italy

2018

Authors: Zangari P, Palma P, Cotugno N, et al.

Published in: J Virus Erad.2018;4: 51–54

Abstract: The first EPIICAL General Assembly meeting was held in an atmosphere of growing optimism. Many novel and exciting proposals for HIV research studies were discussed and are described above. The consortium aims to maintain this integrated developmental research on NDMTs,

Impact of time of ART initiation on HIV specific T cell functionality in perinatally infected young adults

2017

Authors: Rinaldi S, Cotugno N, Pallikkuth S, Palma P, Pahwa S; on behalf of the EPIICAL Consortium

Published: 8th Conference on HIV Persistence

Background Early initiation of antiretroviral therapy (ART) in vertically HIV-infected children provides an opportunity to limit the size of reservoir, but whether and how the time of ART treatment initiation can durably impact host immune responses associated with HIV infection is still unknown.

Congenital Cytomegalovirus. A european expert consensus statement on diagnosis and management

2017

Authors: Luck SE, Wieringa JW, Blazquez-Gamero D, et al.

Published in: Pediatr Infect Dis J. 2017;36(12):1205-1213

 

Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand.

2017

Authors: European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord.

Published inEur J Clin Pharmacol. 2017;73(4):463-468

Background Zidovudine (ZDV) has been associated with risk of haematological toxicity. Safety data from clinical trials is generally limited to 48 weeks. We assessed the short- and mid-term toxicity of ZDV/lamivudine (3TC) fixed-dose combination scored tablets in HIV-infected children followed in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) network.

Qualitative study of the BREATHER trial (Short Cycle antiretroviral therapy): is it acceptable to young people living with HIV?

2017

Authors: Bernays S, Paparini S, Seeley J, Namukwaya Kihika S, Gibb D, Rhodes T.

Published inBMJ Open. 2017;7(2):e012934

Objectives A qualitative study of the BREATHER (PENTA 16) randomised clinical trial, which compared virological control of Short Cycle Therapy (SCT) (5 days on: 2 days off) with continuous efavirenz (EFV)-based antiretroviral therapy (CT) in children and young people (aged 8–24) living with HIV with viral load <50 c/mL to examine adaptation,

“How Do We Start? And How Will They React?” Disclosing to Young People with Perinatally Acquired HIV in Uganda

2017

Authors: Namukwaya S, Paparini S, Seeley J, Bernays S.

Published in: Front Public Health. 2017;5:343.

Abstract: Despite great advances in pediatric HIV care, rates and the extent of full disclosure of HIV status to infected children remain low especially in resource-constrained setting. The World Health Organisation recommends that, by the age of 10-12 years old,

Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa

2017

Authors: Hakim J, Musiime V, Szubert AJ; REALITY Trial Team

Published in: N Engl J Med. 2017;377(3):233-245

Background In sub-Saharan Africa, among patients with advanced human immunodeficiency virus (HIV) infection, the rate of death from infection (including tuberculosis and cryptococcus) shortly after the initiation of antiretroviral therapy (ART) is approximately 10%.

Methods In this factorial open-label trial conducted in Uganda,

Zika genomics urgently need standardized and curated reference sequences

2017

Authors: Theys K, Libin P, Dallmeier K, et al.

Published in: PLoS Pathog. 2017;13(9):e1006528

In this letter, the authors address the need for curation and standardized annotation of ZIKV reference genomes in order to guide researchers and clinicians in genomic analyses and the translation of research findings.

Trends of microcephaly and severe arthrogryposis in three urban hospitals following the Zika, chikungunya and dengue fever epidemics of 2016 in Jamaica

2017

Authors: James-Powell T, Brown Y, Christie CDC, et al.

Published in: West Indian Med J, 2017; 66:10-19 

Introduction Jamaica experienced its maiden Zika virus (ZIKV) epidemic in 2016, while dengue (serotypes 3 and 4) and chikungunya were also circulating.
Aim We describe initial trends in microcephaly and arthrogryposis observed by the clinicians from three urban birthing facilities during late 2016 to early 2017.

Maternal Zika virus disease severity, virus load, prior dengue antibodies, and their relationship to birth outcomes

2017

Authors: Halai UA, Nielsen-Saines K, Moreira ME, et al.

Published in: Clin Infect Dis. 2017;65(6):877-883

Background Congenital Zika virus (ZIKV) syndrome is a newly identified condition resulting from infection during pregnancy. We analyzed outcome data from a mother-infant cohort in Rio de Janeiro in order to assess whether clinical severity of maternal ZIKV infection was associated with maternal virus load,

Update on Zika – What you need to know

2017

Authors: Sáfadi MA, Nascimento-Carvalho CM

Published in: Pediatr Infect Dis J.2017;36(3):333-336

Abstract After remaining related to few sporadic cases in limited regions for more than half century since its discovery, Zika virus (ZIKV) was recently introduced into the Western Hemisphere, first in Brazil and then spreading very rapidly in the Americas. Unexpectedly, an increased incidence of microcephaly and other neurologic malformations in fetuses born to mothers infected with ZIKV during pregnancy was reported in Brazil,

Zika virus disrupts molecular fingerprinting of human neurospheres

2017

Authors: Garcez PP, Nascimento JM, de Vasconcelos JM, et al.

Published in: Sci Rep. 2017 Jan 23;7:40780

Abstract Zika virus (ZIKV) has been associated with microcephaly and other brain abnormalities; however, the molecular consequences of ZIKV to human brain development are still not fully understood. Here we describe alterations in human neurospheres derived from induced pluripotent stem (iPS) cells infected with the strain of Zika virus that is circulating in Brazil.

The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication

2017

Authors: Sacramento CQ, de Melo GR, de Freitas CS, et al.

Published in: Sci Rep.2017 Jan 18;7: 40920

Abstract Zika virus (ZIKV) is a member of the Flaviviridae family, along with other agents of clinical significance such as dengue (DENV) and hepatitis C (HCV) viruses. Since ZIKV causes neurological disorders during fetal development and in adulthood,

Persistent Zika virus detection in semen in a traveler returning to the United Kingdom from Brazil, 2016

2017

Authors: Gaskell KM, Houlihan C, Nastouli E, Checkly AM

Published in: Emerg Infect Dis.2017;23(1):137-139

Abstract Zika virus is normally transmitted by mosquitos, but cases of sexual transmission have been reported. We describe a patient with symptomatic Zika virus infection in whom the virus was detected in semen for 92 days. Our findings support recommendations for 6 months of barrier contraceptive use after symptomatic Zika virus infection.

Acute paralysis and neuro-inflammation in jamaican children during Zika virus and dengue epidemics of 2016

2017

Authors: Melbourne-Chambers R., Christie CD, Greenaway E., Bullock R

Published in: West Indian Med J.2016;65(3):425-430

Abstract Dengue, Chikungunya Fever (CHIKV) and Zika virus (ZIKV) are all transmitted by the Aedes aegypti mosquito and are currently circulating in Jamaica. Jamaica has been experiencing a ZIKV epidemic since February 2016. At the University Hospital of the West Indies (UHWI),

Coinfection with Zika and dengue-2 viruses in a traveler returning from Haiti, 2016: clinical presentation and genetic analysis

2017

Authors: Iovine NM, Lednicky J, Cherabuddi K,  et al.

Published in: Clin Infect Dis. 2017;64(1): 72–75.

Abstract Zika virus and dengue virus serotype 2 were isolated from a patient with travel to Haiti who developed fever, rash, arthralgias, and conjunctivitis. The infecting Zika virus was related to Venezuelan and Brazilian strains but evolved along a lineage originating from strains isolated in 2014 in the same region of Haiti.

12345678910